Production (Stage)
Atara Biotherapeutics, Inc.
ATRA
$7.80
$0.3054.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 219.71% | 79.00% | 68.61% | 73.21% | 57.53% |
| Total Depreciation and Amortization | 29.04% | -8.71% | 1.74% | 10.74% | 14.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.52% | -40.88% | -33.67% | -34.71% | -19.86% |
| Change in Net Operating Assets | -599.85% | -207.89% | 232.76% | -409.23% | -160.01% |
| Cash from Operations | 4.98% | 51.45% | 92.23% | 79.84% | 22.94% |
| Capital Expenditure | -- | -104.55% | 100.00% | 94.19% | 68.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.86% | -65.30% | -123.57% | -85.54% | 364.69% |
| Cash from Investing | 16.86% | -66.05% | -123.66% | -85.46% | 345.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -10.13% | -9.30% | 5.29% | -9.91% | 27.24% |
| Issuance of Common Stock | -- | -- | -- | -86.66% | 1,364.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | 93.55% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,315.38% | -- |
| Cash from Financing | -101.04% | -121.69% | 17,308.17% | -168.79% | 10,172.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -221.01% | 45.00% | -19.87% | -32.71% | 120.92% |